Skip to main content
Industry News
BridgeBio acquires Eidos in $2.8B cash, stock deal

BridgeBio Pharma announced that it will buy Eidos Therapeutics in a cash and stock deal worth $2.83 billion, with the transaction expected to be finalized by the first quarter of next year. Eidos is developing the ATTR cardiomyopathy and polyneuropathy treatment acoramidis.

Full Story: